Basecamp Research said its EDEN family of evolutionary AI models can design therapeutic molecules that enable programmable insertion of large DNA sequences into precise genomic locations across thousands of disease‑relevant sites. The preprint and company materials report EDEN‑designed insertions at over 10,000 loci and functional CAR T‑cells that showed >90% tumor‑cell clearance in vitro. Separately, a Nvidia‑partnered startup disclosed AI‑generated enzymes claimed to insert genes precisely, expanding beyond small edits that typical CRISPR approaches handle. Both announcements stress AI‑driven design of biological tools for gene insertion, with implications for gene therapy modalities that require delivery of larger payloads. Companies cited large proprietary sequence datasets and co‑development funding from NVentures and Nvidia. The advances are preclinical and in preprint, but they signal accelerated industry investment at the intersection of large biological datasets, generative AI and therapeutic gene‑engineering.